3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
14
Carcinoma, Non-Small-Cell Lung
9
Colorectal Neoplasms
7
Stomach Neoplasms
6
Triple Negative Breast Neoplasms
5
Esophageal Squamous Cell Carcinoma
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Pancreatic Neoplasms
3
Melanoma
3
Urinary Bladder Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma, Extranodal NK-T-Cell
2
Liver Neoplasms
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Advanced Biliary Tract Cancer
2
Urothelial Carcinoma Bladder
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Radiation Pneumonitis
1
Interventions
tislelizumab
1
pembrolizumab
1
atezolizumab
1
Water
1
Therapeutics
1
Surgical Procedures, Operative
1
Preoperative Exercise
1
Nutritional Support
1
Immunoglobulins, Intravenous
1
Exercise
1
Ethanol
1
Dosage Forms
1
Biological Therapy
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Urologic Neoplasms
×
tislelizumab
×
Clear all
NCT04922047
2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2
Unknown
6 enrolled